Cellid셀리드
299660 · KOSDAQ · ₩299660 · 셀리드
- Market cap
- ₩63B
- Enterprise value
- ₩79B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −51.0%
- Net margin
- −262.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−55.4% from the high
₩973Today: ₩2,050 – ₩2,145₩4,760
Returns
- 1W−8.8%
- 1M−18.9%
- 3M+19.6%
- 6M−31.2%
- YTD−25.7%
- 1Y−41.5%
- Volume today
- 98,208
- 0.1× the 20-day average
- Traded today
- ₩207M
- Listed shares
- 29,502,977
- EPS (12 months)
- −₩928
- Earnings yield −43.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumWeak-26.3% over the last month; the price is below its 20-day average.
- News impactSome16 news items and filings in two weeks; 0 rated high impact, 2 medium.
Signals describe activity, not recommendations. Not financial advice.
Cellid stock overview
Cellid (셀리드, KRX: 299660) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biopharmaceutical developer built on two platform technologies: CeliVax, a cell-gene therapy-based cancer immunotherapy vaccine platform, and an adenovirus vector platform for infectious disease prevention vaccines. Its shares closed at ₩2,125 on Oct 27, 2026, up 1.92% on the day, giving it a market value of ₩63B.
Key facts
- Market cap
- ₩63B
- Sector
- Biotech & Pharma
- Latest price change
- +1.92%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biopharmaceutical developer built on two platform technologies: CeliVax, a cell-gene therapy-based cancer immunotherapy vaccine platform, and an adenovirus vector platform for infectious disease prevention vaccines.
Quick answers about Cellid
- What does Cellid do?
- The company is a Korean biopharmaceutical developer built on two platform technologies: CeliVax, a cell-gene therapy-based cancer immunotherapy vaccine platform, and an adenovirus vector platform for infectious disease prevention vaccines. It is developing several cancer immunotherapy vaccine candidates and a COVID-19 preventive vaccine, all still in preclinical or clinical stages with no commercial products yet. The company also operates a contract manufacturing (CMO/CDMO) business from its GMP center in Seongnam, Korea, and a small e-commerce unit selling baking ingredients and equipment online.
- What is the market cap of Cellid?
- The market capitalisation of Cellid was ₩63B at the close on Oct 27, 2026.
- Who are the largest shareholders of Cellid?
- According to the latest official filings, the largest reported holders are Kang Chang-yul (8.36%, as of Jul 14, 2026); Kwak Ui-jong (0.03%, as of Jun 30, 2025); National Pension Service (0.02%, as of Dec 31, 2022).
- When is the next earnings report from Cellid?
- Korean companies rarely announce results dates in advance. Based on when Cellid filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Cellid?
- Yes. The National Pension Service held 0.02% of Cellid shares as of Dec 31, 2022.
Company profile
The company is a Korean biopharmaceutical developer built on two platform technologies: CeliVax, a cell-gene therapy-based cancer immunotherapy vaccine platform, and an adenovirus vector platform for infectious disease prevention vaccines. It is developing several cancer immunotherapy vaccine candidates and a COVID-19 preventive vaccine, all still in preclinical or clinical stages with no commercial products yet. The company also operates a contract manufacturing (CMO/CDMO) business from its GMP center in Seongnam, Korea, and a small e-commerce unit selling baking ingredients and equipment online.
Written by AI from the company's latest annual report.
- Korean name
- 셀리드
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 강창율
- Founded
- Dec 2006
- Listed
- Feb 2019
- Listed shares
- 29,502,977
- Fiscal year ends
- Month 12
- Website
- www.cellid.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Lawsuit filed or ruledOct 28, 2026
- Lawsuit filed or ruledOct 28, 2026
- Amended: Shareholders' meeting calledOct 21, 2026
- Reference Document for Proxy Solicitation of Voting RightsOct 21, 2026
- Notice of shareholders' meetingOct 21, 2026
Titles in Korean until English translations are added.
Also known as: Cellid / 셀리드 / 299660 / KRX:299660
Source: KRX statistical information